Sinclair A et al (London) underline in a recent editorial (J Prev Alz Dis 2018;5(2):95-97) the important contribution that Diabetes makes to the aetiology of both vascular and neurodegenerative dementia syndromes.  It has been observed that diabetes in the presence… Continue Reading →

A delayed-start design has been proposed to assess a potential disease-modifying effect in investigational drugs for Alzheimer’s disease that target the underlying disease process.  EXPEDITION3 was a Phase 3, double-blind study with participants randomized to solanezumab (400 mg) or placebo… Continue Reading →